Over 40 Chinese government officials have been held accountable for their neglect of duty and misconduct for manufacturing substandard vaccines, including rabies vaccines, exported to India and other countries, in the country's latest drug-safety scandal.
Rabies vaccines made by the Changchun Changsheng Life Sciences Company, the second largest in China, were found to have violated national standards including usage of expired fluids and falsified production dates. The vaccines were also widely exported, including to India.
Forty government officials, including seven at the provincial level, have been held accountable for their neglect of duty or misconduct in oversight over the substandard vaccines at the company at a meeting presided over by Chinese President Xi Jinping, state-run Xinhua news agency reported today.
The Drug Controller General of India, early this month ordered an immediate withdrawal of rabies vaccines from the market and have also banned its imports from a Chinese manufacturer that allegedly fabricated records.
Also investigation by the Chinese officials into recent vaccine scandal revealed that the batch of DPT vaccines, produced in July 2016 by the Chinese firm were proved substandard due to a short-term equipment failure.
The DPT vaccines were made by Wuhan Institute of Biological Products Co. Ltd.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
